HER-Vaxx will need to commence Ph3 clinical trial which we all know is very expensive to conduct and there's plan of Ph2 clinical trial for PD1-Vaxx to commence this year so IMU has told us about these so-called "shelved" IP but clearly some share holders still haven't listen.
Preferably the Ph2 clinical trial for PD1-Vaxx end up being delayed by IMU and they focus all their resource and fund on the 3 IP with FDA IND which will allow Fast Track designation (VAXINIA), ODD (VAXINIA) and path to registrational clinical trial as these are the assets which will attract BP. IMU is planning to receive Fast Track designation for Azer-Cel which will assist in the path for registrational clinical trial and I can see the same for OASIS as the major compound is CF33 which is used in the VAXINIA clinical trial.
IMU Price at posting:
3.7¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)